In medicine, a stent is a tube usually constructed of a metallic alloy or a polymer. It is inserted into the lumen of an anatomic vessel or duct to keep the passageway open. Stenting is the placement of a stent. A wide variety of stents are used for different medical purposes, ranging from expandable coronary, vascular and biliary stents, to simple plastic tube stents that allow urine to flow between kidney and bladder. "Stent" is also used as a verb to describe the placement of such a device, particularly when a disease such as atherosclerosis has pathologically narrowed a structure such as an artery.
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.
Intravascular ultrasound (IVUS) or intravascular echocardiography is a medical imaging methodology using a specially designed catheter with a miniaturized ultrasound probe attached to the distal end of the catheter. The proximal end of the catheter is attached to computerized ultrasound equipment. It allows the application of ultrasound technology, such as piezoelectric transducer or CMUT, to see from inside blood vessels out through the surrounding blood column, visualizing the endothelium of blood vessels.
Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat narrowing of the coronary arteries of the heart found in coronary artery disease. The process involves combining coronary angioplasty with stenting, which is the insertion of a permanent wire-meshed tube that is either drug eluting (DES) or composed of bare metal (BMS). The stent delivery balloon from the angioplasty catheter is inflated with media to force contact between the struts of the stent and the vessel wall, thus widening the blood vessel diameter. After accessing the blood stream through the femoral or radial artery, the procedure uses coronary catheterization to visualise the blood vessels on X-ray imaging. After this, an interventional cardiologist can perform a coronary angioplasty, using a balloon catheter in which a deflated balloon is advanced into the obstructed artery and inflated to relieve the narrowing; certain devices such as stents can be deployed to keep the blood vessel open.
Drug-eluting stents (DES) are a type of stent and a medical drug delivery device used in the treatment of various medical conditions, with the primary application being the treatment of coronary artery disease. Stents are inserted into narrowed coronary arteries, primarily caused by atherosclerosis.These stents gradually release a drug compound that inhibits cellular growth, inhibiting the potential for blockage within the stent area itself after being placed in the diseased coronary artery. This in-stent blockage is most often caused by excessive cell proliferation or thrombi .Anticoagulation therapy post stenting has become an established practice.
Phosphorylcholine is the hydrophilic polar head group of some phospholipids, which is composed of a negatively charged phosphate bonded to a small, positively charged choline group. Phosphorylcholine is part of the platelet-activating factor; the phospholipid phosphatidylcholine and sphingomyelin, the only phospholipid of the membrane that is not built with a glycerol backbone. Treatment of cell membranes, like those of RBCs, by certain enzymes, like some phospholipase A2, renders the phosphorylcholine moiety exposed to the external aqueous phase, and thus accessible for recognition by the immune system. Antibodies against phosphorylcholine are naturally occurring autoantibodies that are created by CD5+/B-1 B cells and are referred to as non-pathogenic autoantibodies.
The history of invasive and interventional cardiology is complex, with multiple groups working independently on similar technologies. Invasive and interventional cardiology is currently closely associated with cardiologists, though the development and most of its early research and procedures were performed by diagnostic and interventional radiologists.
Biosensors International Group is a medical device company that specializes in developing, manufacturing and licensing technologies for use in interventional cardiology procedures and critical care. The company was listed in the Mainboard of the Singapore Exchange (SGX) in May 2005. The global headquarters of the company are located in Singapore, where the main manufacturing facilities and R&D centers are hosted. The European headquarters are in Morges, Switzerland; this Swiss office is also the Legal Manufacturer of BioMatrix, the current leading product of the company.
Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan.
A coronary stent is a tube-shaped device placed in the coronary arteries that supply blood to the heart, to keep the arteries open during the treatment of coronary heart disease. It is used in a procedure called percutaneous coronary intervention (PCI). Coronary stents are divided into two broad types - drug-eluting and bare metal, as of 2023 drug-eluting stents were used in more than 90% of all PCI procedures. Stents reduce angina and have been shown to improve survival and decrease adverse events after a patient has suffered a heart attack - acute myocardial infarction.
Zotarolimus is an immunosuppressant. It is a semi-synthetic derivative of sirolimus (rapamycin). It was designed for use in stents with phosphorylcholine as a carrier. Zotarolimus, or ABT-578, was originally used on Abbott's coronary stent platforms to reduce early inflammation and restenosis; however, Zotarolimus failed Abbott's primary endpoint to bring their stent/drug delivery system to market. The drug was sold/distributed to Medtronic for use on their stent platforms, which is the same drug they use today. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications associated with stent use, development of thrombosis which impedes the efficiency of coronary stents, haemorrhagic and restenosis complications are problems associated with stents.
A bare-metal stent is a stent made of thin, uncoated (bare) metal wire that has been formed into a mesh-like tube. The first stents licensed for use in cardiac arteries were bare metal – often 316L stainless steel. More recent "second generation" bare-metal stents have been made of cobalt chromium alloy. While plastic stents were first used to treat gastrointestinal conditions of the esophagus, gastroduodenum, biliary ducts, and colon, bare-metal stent advancements led to their use for these conditions starting in the 1990s.
In medicine, a stent is any device which is inserted into a blood vessel or other anatomical internal duct to expand it to prevent or alleviate a blockage. Traditionally, such devices are fabricated from metal mesh and remain in the body permanently or until removed through further surgical intervention. A bioresorbable stent serves the same purpose, but is manufactured from a material that may dissolve or be absorbed in the body.
Alvimedica is a manufacturer of coronary stents, balloon catheters, diagnostic and guiding catheters. The company was founded in 2007 by Turkish businessmen and scientists living in Denmark and Sweden. The major intention of the company is investing in small and medium size medical device manufacturers to enable them to compete globally. The company made its first investment move by purchasing a medical device company called Nemed in Turkey in 2007. Following this, the company purchased an American company called In-Vivo, a manufacturer of angioplasty and angiography catheters, and one of the suppliers of Abbott Laboratories.
Genous is an endothelial progenitor cell (EPC) capture technology manufactured by OrbusNeich that promotes the accelerated natural healing of the vessel wall after stent implantation. The pro-healing technology has an antibody surface coating that captures circulating CD34+ endothelial progenitor cells to the device, forming a functional endothelial layer over the stent to protect against thrombus and minimize restenosis.
A dual therapy stent is a coronary artery stent that combines the technology of an antibody-coated stent and a drug-eluting stent. Currently, second-generation drug-eluting stents require long-term use of dual-antiplatelet therapy, which increases the risk of major bleeding occurrences in patients. Compared to drug-eluting stents, dual therapy stents have improved vessel regeneration and cell proliferation capabilities. As a result, dual therapy stents were developed to reduce the long-term need for dual-antiplatelet therapy.
Ashok Seth is an Indian interventional cardiologist, credited with the performance of over 50,000 angiograms and 20,000 angioplasties, which has been included in the Limca Book of Records, a book for achievements and records from an Indian perspective. He is a Fellow of the Royal Colleges of Physicians of London, Edinburgh and Ireland and serves as the chief cardiologist, holding the chairs of the department of cardiovascular sciences and cardiology council at the Fortis Healthcare. Seth, a recipient of the Order of Isabella the Catholic, was honored by the Government of India with the fourth highest Indian civilian award of Padma Shri, in 2003, followed by Padma Bhushan, the third highest Indian civilian award, in 2015.
Donald S. Baim was a researcher and clinician in the field of interventional cardiology. Baim's primary research focused on coronary blood flow, catheter intervention in heart disease, and congestive heart failure. His work helped to shift the use of catheters from a purely diagnostic tool to a therapeutic tool. After receiving a medical degree from Yale and initial medical training, residency and a fellowship at Stanford University Medical Center, Baim spent the bulk of his career at Beth Israel Hospital and at the Brigham and Women's Hospital in Boston. In 1993, Baim founded the Beth Israel Hospital's Cardiovascular Data Analysis Center (CDAC) -- later to be named Harvard Clinical Research Institute (HCRI). Baim died of cancer in November 2009. In October 2016, HCRI changed its name to the Baim Institute for Clinical Research.
Alfredo E. Rodríguez is an Argentine interventional cardiologist, clinical researcher, and author. He is the Chief of Interventional Cardiology Service at Otamendi Hospital and Director and Founder of the Cardiovascular Research Center (CECI) a non -profit Research Organization in Buenos Aires Argentina.
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 100 countries and has employed 4000 people, as of 2022.
US$793.493Million (2019 Annual) [1]